TALS | Talaris Therapeutics, Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	2.6900 - 2.7950
52 Week Range	0.8900 - 3.29
Beta	N/A
Implied Volatility	N/A
IV Rank	N/A
Day's Volume	303,484
Average Volume	142,922
Shares Outstanding	42,810,600
Market Cap	116,444,832
Sector	Healthcare
Industry	Biotechnology
IPO Date	2021-05-07

Valuation
Profitability
Growth
Health
P/E Ratio	-1.56
Forward P/E Ratio	-2.96
EPS	-1.74
1YR Price Target	2.50
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	84
Country	USA
Website	TALS

Talaris Therapeutics Inc is a late-clinical stage biotechnology company. It is developing transformative cell therapies with the potential to eliminate the burden of chronic immunosuppression for organ transplant recipients as well as induce durable remissions in patients with severe autoimmune and immune-mediated disorders.

TALS's peers: ACET, CGEM, EWTX, HOWL, RDUS, VOR, XOMA, OABI

*Chart delayed

Analyzing fundamentals for TALS we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is passable. For more detailed analysis please see TALS Fundamentals page.

Watching at TALS technicals we can see that long-term trend is bullish, while middle-term trend is bearish, as well as bearish short-term trend. More technicals details can be found on TALS Technicals page.